77 results
Page 3 of 4
424B5
6s1d h13l5524yi5g
3 Jun 19
Prospectus supplement for primary offering
4:01pm
8-K
m0eat6 qp
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
8-K
EX-99.1
sthmgf0vthlbu2
21 Mar 19
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
4:40pm
424B5
jjrtm082k i2fxd
4 May 18
Prospectus supplement for primary offering
6:13am
8-K
EX-1.1
cx29p6h06d39el65ll7
4 May 18
Sientra Commences Public Offering of Common Stock
6:07am
424B5
c0tiuhc 969jtahzdlr
30 Apr 18
Prospectus supplement for primary offering
7:05am